Floatz logo

(1S,2S)-(+)-PSEUDOEPHEDRINE

Migraine

ClinvestSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

107 Active assets in the Migraine cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
mk-1602
H. Lundbeck A/S
Phase 4BBB

View all 50 →

Same molecule, other indications

(1S,2S)-(+)-PSEUDOEPHEDRINE is also rated in:

sinusitisDormant
BB
Indicative ·
69 / 100
View asset →
pure autonomic failureDormant
CC
Indicative ·
47 / 100
View asset →
multiple system atrophyDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →